SC
BDTX icon

Steven Cohen’s Black Diamond Therapeutics BDTX Stock Holding History

Steven Cohen’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,985
Closed -$215K – 4015
2026
Q1 		$215K Sell
100,985
-95,756
-49% -$228K ﹤0.01% 3494
2025
Q4 		$478K Buy
+196,741
New +$697K ﹤0.01% 3261
2024
Q4 		– Sell
-697,125
Closed -$3.03M – 2088
2024
Q3 		$3.03M Buy
+697,125
New +$3.79M 0.01% 1038
2023
Q4 		– Sell
-1,115,000
Closed -$3.2M – 2175
2023
Q3 		$3.2M Sell
1,115,000
-885,000
-44% -$3.26M 0.01% 1019
2023
Q2 		$10.1M Buy
+2,000,000
New +$4.08M 0.03% 581
2021
Q1 		– Sell
-605,000
Closed -$19.4M – 964
2020
Q4 		$19.4M Buy
+605,000
New +$19.9M 0.09% 291

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Steven Cohen's BDTX Position: Q2 2026 in Review

Steven Cohen sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 100,985 shares — an estimated $215K sold.

Steven Cohen first reported a position in BDTX in Q4 2020 and held it in 6 quarters. The position peaked at $19.4M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Steven Cohen reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 100,985 Black Diamond Therapeutics shares in Q2 2026, an estimated $215K.
  • Steven Cohen first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 6 quarters.
  • Steven Cohen's Black Diamond Therapeutics position peaked at $19.4M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.